Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirogacestat - SpringWorks Therapeutics

Drug Profile

Nirogacestat - SpringWorks Therapeutics

Alternative Names: Nirogacestat hydrobromide; PF 3084014; PF-03084014; PF-03084014-04

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Jules Bordet Institute; Pfizer; SpringWorks Therapeutics
  • Class Amides; Antineoplastics; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibroma
  • Phase II Pancreatic cancer
  • No development reported Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Discontinued Alzheimer's disease; Breast cancer

Most Recent Events

  • 24 Sep 2019 Nirogacestat - SpringWorks Therapeutics receives Orphan Drug status for Soft tissue sarcoma in European Union
  • 30 Aug 2019 Nirogacestat receives Breakthrough Therapy status for Fibroma (Recurrent or refractory, Inoperable/Unresectable) in USA
  • 03 Jul 2019 SpringWorks Therapeutics and GlaxoSmithKline plans a phase Ib trial for Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top